Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

AAN 2023: Zilucoplan eases symptoms in all subgroups in trial

Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients participating in the Phase 3 RAISE clinical trial. Trial data showed treatment effects were consistent, regardless of sex, age, disease duration, prior use of certain treatments, or thymoma status. Findings…

Robot-assisted thymectomy ‘safe and feasible’ in MG: Study

Robot-assisted surgery to remove the thymus is generally safe for people with myasthenia gravis (MG), with most patients who undergo the procedure seeing a reduction in symptom severity afterward, a study reports. “This retrospective follow-up study showed that robotic thymectomy [thymus removal surgery] is safe and feasible in patients…

Vyvgart approved as add-on in UK for adults with AChR-positive gMG

Vyvgart (efgartigimod) won approval in the U.K. as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor (AChR)-targeting antibodies. “We are pleased to announce this latest regulatory approval of Vyvgart, another exciting advancement toward our vision of making our…

Health Canada Approves Ultomiris for AChR-positive gMG

Ultomiris (ravulizumab-cwvz) has been approved in Canada to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common type of MG-causing antibody. The announcement came less than a year after Ultomiris was approved for the condition in the U.S., and…